Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol

Cardiology Journal

Volumn 20, Issue 2, 2013, Pages 144-151

  Nessler, Jadwiga ^a   Nessler, Bohdan ^a   Golebiowska Wiatrak, Renata ^a   Palka, Ilona ^a   Gackowski, Andrzej ^a   Kitlinski, Mariusz ^b   Melander, Olle ^c   Fedorowski, Artur ^b,c  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Beta blocker; Biological markers; C reactive protein; Endothelin 1; Heart failure; Natriuretic peptides

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARVEDILOL; ENDOTHELIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOPULMONARY EXERCISE TEST; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; SINUS BRADYCARDIA;

ADRENERGIC BETA-ANTAGONISTS; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARBAZOLES; ENDOTHELIN-1; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POLAND; PROPANOLAMINES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 84885217666     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0027     Document Type: Article

References (26)

1. Braunwald E. Shattuck lecture: Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med, 1997; 337: 1360-1369.
2. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008; 29: 2388-2442.
3. Braunwald E. Biomarkers in heart failure. N Engl J Med, 2008; 358: 2148-2159.
4. Nagatomo Y, Yoshikawa T, Kohno T et al. Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J Card Fail, 2007; 13: 365-371.
5. Fujimura M, Akaike M, Iwase T et al. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure. Acta Cardiol, 2009; 64: 589-595.
6. Nessler J, Nessler B, Kitlinski M, Gackowski A, Piwowarska W, Stepniewski M. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-αlpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol. Kardiol Pol, 2008; 66: 144-151.
7. Nessler J, Nessler B, Kitlinski M, Stepniewski M, Piwowarska W. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol. Cardiol J, 2008; 15: 329-337.
8. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach. J Am Coll Cardiol, 2010; 56: 392-406.
9. Cardiology WGoCREPaWGoHFotESo. Recommendations for exercise testing in chronic heart failure patients. Eur Heart J, 2001; 22: 37-45.
10. Balady GJ, Arena R, Sietsema K et al. Clinician's Guide to cardiopulmonary exercise testing in adults: A scientific statement from the American Heart Association. Circulation, 2010; 122: 191-225.
11. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long--term effects of metoprolol versus carvedilol. Circulation, 2000; 102: 546-551.
12. Palazzuoli A, Bruni F, Puccetti L et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail, 2002; 4: 765-770.
13. Lombardo RM, Reina C, Abrignani MG, Rizzo PA, Braschi A, De Castro S. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs, 2006; 6: 259-263.
14. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: A potential of hormone-guided treatment. Am Heart J, 2001; 141: 925-932.
15. Baran D, Horn EM, Hryniewicz K, Katz SD. Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure. Drugs, 2000; 60: 997-1016.
16. Hartmann F, Packer M, Coats AJ et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation, 2004; 110: 1780-1786.
17. Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther, 2008; 22: 305-311.
18. Neuhold S, Huelsmann M, Strunk G et al. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem, 2010; 56: 121-126.
19. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009; 119: e391-479.
20. Bohm M, Voors AA, Ketelslegers JM et al. Biomarkers: Optimizing treatment guidance in heart failure. Clin Res Cardiol, 2011; 100: 973-981.
21. Tang WH, Shrestha K, Martin MG et al. Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure. J Card Fail, 2010; 16: 635-640.
22. Somasundaram P, Sung BH, Mousa SA, Wilson MF. Acute congestive heart failure and tumor necrosis factor alpha. Am J Geriatric Cardiol, 2000; 9: 76-80.
23. Osman R, L'Allier PL, Elgharib N, Tardif JC. Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag, 2006; 2: 221-237.
24. Smith JG, Newton-Cheh C, Almgren P et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol, 2010; 56: 1712-1719.
25. Yue TL, Cheng HY, Lysko PG et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther, 1992; 263: 92-98.
26. Ruffolo RR, Jr., Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol, 1990; 38 (suppl. 2): S82-S88.